NOVOCURE LTD
NVCRNASDAQ🏆 #2046 by market capUS Equity
$14.14▼ $0.49 (−3.35%)
Market closed · at closeTrack NVCR
Get earnings, price moves & breaking news on Telegram
24h▼ 3.4%
7d▼ 6.4%
14d▼ 1.8%
30d▼ 11.6%
ytd▲ 9.5%
1y▲ 4.9%
🏦Market Cap
$1.65B
Small Cap
📈Revenue Growth (YoY)
10.9%
Healthy
📊Gross Margin
76.1%
High
💵FCF Margin
2.3%
Thin
⚖️P/S Ratio
2.4x
Cheap
Otter Score
72
Strong
Trading Snapshot
- Day Range
- $13.85 – $14.64
- 52-Week Range
- $9.82 – $21.45
- Volume (shares)
- 257,413
- Avg Volume (shares)
- —
- Shares Outstanding
- 116.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 2.4x
- EPS (TTM)
- $-1.31
- Dividend Yield
- —
- Dilution (1yr)
- +3.4%
NOVOCURE LTD
NVCRFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$655M▲ +8.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.5%▼ −3.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$154M▼ −9.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$76M▲ +9.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
111.5M▲ +3.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$187M▲ +$333M YoY
StockOtter · stockotter.spaceAbout NOVOCURE LTD
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100
Analyst data unavailable.
Latest News & Updates
News unavailable.